{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HSV+2+Formulation+1",
    "query": {
      "intervention": "HSV 2 Formulation 1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HSV+2+Formulation+1&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T18:53:51.230Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00057330",
      "title": "HerpeVac Trial for Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Simplex Infection"
      ],
      "interventions": [
        {
          "name": "HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 8323,
      "start_date": "2003-01-14",
      "completion_date": "2009-08-22",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057330"
    },
    {
      "nct_id": "NCT04762511",
      "title": "A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "Lower dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Medium dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-02",
      "completion_date": "2021-05-26",
      "has_results": false,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Rochester, New York",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762511"
    },
    {
      "nct_id": "NCT01448616",
      "title": "Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Simplex Type II"
      ],
      "interventions": [
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vaginal Gel",
          "type": "DRUG"
        },
        {
          "name": "Vaginal TFV Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 73,
      "start_date": "2012-02",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01448616"
    },
    {
      "nct_id": "NCT00448227",
      "title": "Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "famciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "1 Month to 1 Year"
      },
      "enrollment_count": 18,
      "start_date": "2007-10",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-02-11",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448227"
    },
    {
      "nct_id": "NCT05298254",
      "title": "A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "Non-adjuvanted HSV formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Non-adjuvanted HSV formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Non-adjuvanted HSV formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV formulation 1 with adjuvant 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV formulation 2 with adjuvant 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV formulation 3 with adjuvant 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV formulation 1 with adjuvant 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV formulation 2 with adjuvant 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSV formulation 3 with adjuvant 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "HSVTI_F1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSVTI_F2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 505,
      "start_date": "2022-03-07",
      "completion_date": "2025-06-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05298254"
    },
    {
      "nct_id": "NCT00098046",
      "title": "Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chickenpox",
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "famciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "1 Year to 12 Years"
      },
      "enrollment_count": 76,
      "start_date": "2005-07",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-09-26",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00098046"
    },
    {
      "nct_id": "NCT00802464",
      "title": "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "Herpes zoster vaccine GSK1437173A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2009-01-12",
      "completion_date": "2010-07-02",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Edison",
          "state": "New Jersey"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802464"
    },
    {
      "nct_id": "NCT00331032",
      "title": "VivaGel™ in Healthy Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Simplex II"
      ],
      "interventions": [
        {
          "name": "3% w/w SPL7013 Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "24 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 24 Years · Female only"
      },
      "enrollment_count": 56,
      "start_date": "2006-12",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2013-08-23",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00331032"
    },
    {
      "nct_id": "NCT00611949",
      "title": "Comparison of 2 Vials of Components of a Synthetic Geranium Oil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "Geranium oil",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2002-05",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-18",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611949"
    },
    {
      "nct_id": "NCT04398706",
      "title": "Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Immunisation",
        "Diphtheria Immunisation",
        "Tetanus Immunisation",
        "Pertussis Immunisation",
        "Hepatitis B Immunisation",
        "Haemophilus Influenzae Type b Immunisation",
        "Polio Immunisation",
        "Measles Immunisation",
        "Rubella Immunisation",
        "Varicella Immunisation",
        "Mumps Immunisation"
      ],
      "interventions": [
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varicella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles, Mumps, and Rubella Virus Vaccine Live",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus Vaccine, Live, Oral, Pentavalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine* [Recombinant] *as applicable",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "42 Days to 15 Months"
      },
      "enrollment_count": 852,
      "start_date": "2020-05-22",
      "completion_date": "2023-08-10",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-09-15T18:53:51.230Z",
      "location_count": 49,
      "location_summary": "Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04398706"
    }
  ]
}